10-K: Clarivate Reports Mixed 2025 Results Amid Strategic Shift

Sentiment:

Annual Report 24 February 2026 6:04 AM

Clarivate Plc reported a 4% revenue decline in 2025 to $2.46 billion, alongside a significantly reduced net loss and increased free cash flow, as it executes its Value Creation Plan focused on AI innovation and business streamlining.

Capital raiseIn May 2025, the company entered into an incremental $500.0 million tranche of term loans under its term loan facility.The company may be required, or could elect, to seek additional funding through public or private equity or debt financings in the future.

Summary

Revenues for the year ended December 31, 2025, decreased by 4.0% to $2,455.2 million from $2,556.7 million in 2024, primarily due to product group wind-downs and divestitures.
Net loss significantly improved to $(201.1) million in 2025, compared to a net loss of $(636.7) million in 2024.
Adjusted EBITDA decreased by 5.5% to $1,001.8 million in 2025 from $1,060.4 million in 2024, with the Adjusted EBITDA margin declining to 40.8% from 41.5%.
Free cash flow increased by 2% to $365.3 million in 2025, up from $357.5 million in 2024, driven by a reduction in capital expenditures.
The annual renewal rate for subscription-based agreements improved to 92.5% in 2025, up from 91.9% in 2024.
Goodwill impairment charges were substantially lower at $15.0 million in 2025, compared to $540.7 million in 2024.
The company repurchased approximately 56.0 million ordinary shares for $224.5 million in 2025 at an average price of $4.01 per share.
Total debt outstanding decreased to $4,469.9 million as of December 31, 2025, from $4,571.1 million in 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as mixed but with positive underlying trends. While revenue and Adjusted EBITDA declined, these were partially attributed to strategic wind-downs. The significant improvement in net loss, increased free cash flow, and higher renewal rates suggest operational stabilization and effective execution of the Value Creation Plan, positioning the company for potential future growth despite ongoing legal challenges.

Positives

Net loss significantly improved to $(201.1) million in 2025 from $(636.7) million in 2024.
Free cash flow increased by 2% to $365.3 million in 2025, primarily due to a significant reduction in capital expenditures.
The annual renewal rate for subscription-based license agreements improved to 92.5% in 2025, up from 91.9% in 2024.
Goodwill impairment charges were substantially lower at $15.0 million in 2025, a significant reduction from $540.7 million in 2024, indicating improved asset stability.
Total debt outstanding decreased to $4,469.9 million as of December 31, 2025, from $4,571.1 million in 2024, reflecting debt reduction efforts.
Organic annualized contract value (ACV) grew 1.8% in 2025, driven by improved product pricing.

Negatives

Revenues decreased by 4.0% to $2,455.2 million in 2025, primarily due to product group wind-downs and divestitures.
Adjusted EBITDA decreased by 5.5% to $1,001.8 million in 2025, and the Adjusted EBITDA margin declined to 40.8% from 41.5%.
Organic revenue growth was negative at -0.1% in 2025.
Restructuring and other impairments increased to $50.7 million in 2025 from $19.6 million in 2024, reflecting ongoing strategic adjustments.
The company continues to report a net loss, although it has significantly narrowed.

Risks

Dependence on third parties, including public sources, for data, information, and other services, with potential for unpredicted price increases and unfavorable licensing terms.
Increased access to free or relatively inexpensive information sources, including general-purpose AI models, may reduce demand for products and services.
Operating in a highly competitive industry with rapid technological changes and evolving customer demands, including competition from established companies and new AI-driven entrants.
Inability to maintain high annual renewal rates for subscription-based and re-occurring arrangements, which constitute approximately 83% of revenues.
Failure of products and services to achieve and maintain broad market acceptance, or inability to keep pace with rapidly changing technology, evolving industry standards, and changing regulatory requirements, particularly concerning AI.
Reductions in customers' research budgets or government funding, which could adversely affect business, especially for academic institutions and life sciences companies.
The Value Creation Plan may not be successful or may not lead to increased shareholder value, and its implementation could be costly and disruptive.
Loss of, or inability to attract and retain, key personnel, including experts in research, analysis, sales, marketing, product development, and management.
Ineffectiveness of business continuity and recovery plans against unexpected disruptions such as human error, military actions, cyberattacks, natural disasters, or infrastructure failures.
Inability to derive fully the anticipated benefits from organic growth, existing or future acquisitions, joint ventures, investments, or dispositions, including anticipated revenue and cost synergies.
Exposure to increased risks from international operations, including differing legal/regulatory requirements, political instability, international hostilities (e.g., Israel), adverse tax consequences, and currency fluctuations.
Damage to brand and reputation due to external perceptions or poor representation by sales agents.
High level of indebtedness could adversely affect business, financial condition, and results of operations, making it difficult to satisfy debt obligations or obtain additional financing.
Potential for future goodwill and other intangible asset impairment charges if macroeconomic conditions worsen, share price declines, or actual results fall short of projections.
Failure to obtain, maintain, protect, defend, or enforce intellectual property and other proprietary rights, including challenges to trademarks, copyrights, and patents, and unauthorized use of content by AI products.
Uncertainty in the development, deployment, and use of AI in products and services, potentially leading to operational/reputational damage, competitive harm, liability, and additional costs due to flaws, biases, or data rights issues.
Risks related to the rapidly changing regulation of AI and other evolving technologies, which could increase compliance costs and expose the company to legal/regulatory risks.
Disruption in or unauthorized access to or breaches of computer systems, including those of third parties, due to cybersecurity threats, cyberattacks, or aging technology assets.
Failure to comply with applicable data privacy and cybersecurity laws, rules, and regulations, which could harm reputation and business or expose the company to fines and enforcement action.
Intellectual property litigation, including claims related to content provided using products and services, could result in reputational damage and significant costs.
Use of open-source software could negatively affect the ability to offer solutions and subject the company to possible litigation due to license requirements or security vulnerabilities.

Future Outlook

The company plans to continue executing its Value Creation Plan in 2026, focusing on accelerating AI innovation at scale, strengthening commercial execution to drive organic ACV and recurring revenue growth, and driving efficiency and margin expansion through AI adoption. It also intends to streamline its business model by completing product group wind-downs started in 2025 and further transitioning from transactional sales to subscriptions. Capital expenditures are estimated to be approximately $250 million in 2026, primarily for product and content development, with an additional $210 million expected for cloud computing services and software license costs.

Management Comments

Matitiahu Shem Tov, CEO, and Jonathan M. Collins, CFO, certified that the Annual Report on Form 10-K fairly presents, in all material respects, the financial condition and results of operations and cash flows of the registrant.
Management believes that cash flow from operations, available cash on hand, borrowing capacity, and access to capital markets will be adequate to service debt, meet liquidity needs, and fund capital expenditures and other business plans for both the next 12 months and the foreseeable future.

Industry Context

StockSavvy.ai notes that Clarivate's strategic pivot towards AI innovation and a subscription-based model aligns with broader industry trends in the information services sector, where data analytics and AI-driven insights are becoming critical competitive differentiators. The divestitures and product wind-downs reflect a common strategy among established players to shed non-core assets and focus on high-growth, high-margin areas, particularly in the evolving landscape of academic, intellectual property, and life sciences intelligence. The increased access to free or inexpensive information, including general-purpose AI models, poses a significant challenge across the industry, necessitating continuous innovation and value demonstration to maintain market share and pricing power.

Comparison to Industry Standards

Clarivate's annual renewal rate of 92.5% is strong and generally competitive within the subscription-based information services industry, often compared to peers like FactSet Research Systems Inc. and S&P Global Inc., which also rely on high customer retention.
The decline in Adjusted EBITDA margin to 40.8% suggests some pressure on profitability, potentially due to strategic investments or revenue mix shifts, which warrants comparison with the margins of industry leaders like Gartner, Inc. or MSCI Inc. to assess relative efficiency.
The significant reduction in goodwill impairment charges in 2025, compared to substantial impairments in 2023 and 2024, indicates a stabilization of asset valuations, a positive sign when contrasted with companies that may still be grappling with overvalued acquisitions from previous periods.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Policy Adoption	Adopted an Insider Trading Policy on July 23, 2025, governing the purchase, sale, and other dispositions of company securities by directors, officers, and employees.	July 23, 2025	Enhances compliance with insider trading laws and regulations, promoting transparency and integrity in securities transactions by company affiliates.
Share Repurchase Authority Update	Shareholder approval obtained on May 7, 2025, updating the previous share repurchase authority to allow open-market purchases of up to 100 million ordinary shares through May 6, 2030, at a price range of $1 to $35 per share.	May 7, 2025	Provides management with greater flexibility and a longer timeframe to execute share repurchases, potentially enhancing shareholder value and capital allocation efficiency.

Legal Proceedings

Ongoing securities class action complaints filed in the U.S. District Court for the Eastern District of New York, consolidated on May 18, 2022. Allegations include weaknesses in internal controls, financial reporting errors (related to a 2020 business combination and 2022 restatements), false/misleading statements on product quality, organic revenues/growth, and undisclosed business model changes. Motions to dismiss are pending.
A separate but related class action filed in Pennsylvania state court on June 7, 2022, under the Securities Act of 1933, with substantially similar allegations regarding offering documents for June and September 2021 share issuances. The court dismissed the second amended complaint without prejudice on February 18, 2026, allowing the plaintiff to file a third amended complaint.
The company believes the claims alleged against it lack merit and will vigorously defend against them. The reasonably possible loss or range of loss, if any, arising from these matters cannot be estimated at this early stage of proceedings.

Stakeholder Impact

Shareholders: Impacted by the 4% revenue decline and 5.5% Adjusted EBITDA decrease, but also by the significantly reduced net loss, increased free cash flow, and ongoing share repurchase program. The Value Creation Plan aims for long-term value creation, but current legal proceedings introduce uncertainty.
Employees: Affected by restructuring activities, including additional reductions in force and lease rationalization activities planned for 2026 as part of the Value Creation Plan. The company emphasizes enhancing colleague experience and attracting/retaining talent.
Customers: The focus on AI innovation, strengthening commercial execution, and transitioning to subscription models aims to improve product offerings and customer engagement. Product group wind-downs in A&G and LS&H segments may impact some customer relationships.
Creditors: The decrease in total debt outstanding and increased free cash flow are positive for creditors, indicating improved debt servicing capacity. The company's ability to meet debt obligations is tied to future cash flow generation and access to capital markets.

Next Steps

Continue executing the Value Creation Plan in 2026, focusing on accelerating AI innovation at scale.
Strengthen commercial execution to accelerate organic annualized contract value (ACV) and recurring revenue growth.
Deepen customer engagement to drive sustainable account growth and enhance sales productivity through AI-powered insights.
Utilize agentic AI to drive operational efficiency and margin expansion across the organization.
Complete product group wind-downs started in 2025 within the Academia & Government (A&G) and Life Sciences & Healthcare (LS&H) segments.
Further transition from transactional sales to subscriptions.
Incur approximately $25 million of additional costs in 2026 related to the Value Creation Plan, primarily for reductions in force and lease rationalization activities.
Estimate capital expenditures of approximately $250 million during 2026, primarily for product and content development.
Expect to incur approximately $210 million in 2026 for cloud computing services and software license costs.
Potentially refinance, redeem, repurchase, or retire outstanding debt in open market purchases, privately negotiated transactions, tender offers, or otherwise.

Key Dates

Date	Description
December 31, 2020	Starting point for the 5-year cumulative total return comparison graph.
July 30, 2020	Beginning of the putative class period for securities class action complaints.
October 1, 2020	Date of Investor Rights Agreement and Registration Rights Agreement.
October 31, 2019	Date of the original Credit Agreement.
December 1, 2021	Date of First Supplemental Indenture to the 3.875% senior secured notes due 2028 and 4.875% senior notes due 2029.
December 27, 2021	Disclosure of an error in accounting treatment of an equity plan related to the 2020 business combination with CPA Global.
Fourth quarter of 2021	Approval of the ProQuest Acquisition Integration restructuring plan.
February 2, 2022	End of the putative class period for securities class action complaints.
February 3, 2022	Issuance of related restatements of previously issued financial statements.
February 2022	Board approved a share repurchase program of up to $1,000.0 million through December 31, 2023.
January-March 2022	Three putative securities class action complaints filed in the United States District Court for the Eastern District of New York.
May 18, 2022	Securities class action complaints consolidated into a single proceeding.
June 7, 2022	A separate class action filed in Pennsylvania state court under the Securities Act of 1933.
August 8, 2022	Plaintiffs filed a consolidated amended complaint in the New York securities class action.
June 23, 2023	Court order allowing plaintiffs limited leave to amend in the New York securities class action.
July 14, 2023	Plaintiffs filed an amended complaint in the New York securities class action.
July 2023	Entered into a $100.0 million cross-currency swap maturing in November 2026 to mitigate foreign currency exposure.
Second quarter of 2023	Agreed to sell Valipat and approved the Segment Optimization restructuring plan.
Fourth quarter of 2023	Performed annual goodwill impairment assessment, resulting in a $847.7 million charge for IP and LS&H reporting units.
December 31, 2023	End date for the previous share repurchase program authorization.
March 4, 2024	Date of Investment Agreement with Exor N.V.
April 2024	Completed the sale of the Valipat product group, recognizing a loss of $14.8 million.
Second quarter of 2024	Recognized a goodwill impairment charge of $302.8 million for the LS&H reporting unit.
June 3, 2024	All 14.4 million outstanding shares of 5.25% Series A Mandatory Convertible Preferred Shares automatically converted into 55.3 million ordinary shares.
August 29, 2024	Plaintiff filed a second amended complaint in the Pennsylvania state court class action.
September 2024	Recorded $13.8 million of goodwill associated with a small acquisition within the IP reporting unit, which was immediately impaired.
Fourth quarter of 2024	Completed the sale of the ScholarOne product group for net cash proceeds of $103.6 million, recognizing a gain of $69.5 million.
December 2024	Board authorized a new share repurchase program of up to $500.0 million for two years, from January 1, 2025, through December 31, 2026.
December 2024	Board approved the wind-down of three product groups within the LS&H and A&G segments, recording an intangible assets impairment charge of $75.0 million.
Fourth quarter of 2024	Performed annual goodwill impairment assessment, resulting in a $149.1 million charge for the LS&H reporting unit.
January 1, 2025	Beginning of the two-year share repurchase program authorized in December 2024.
May 7, 2025	Shareholder approval obtained for an updated share repurchase authority, allowing open-market purchases of up to 100 million ordinary shares through May 6, 2030.
May 2025	Entered into an incremental $500.0 million tranche of term loans and used proceeds to redeem $500.0 million of Senior Secured Notes due 2026.
June 2025	Entered into cross-currency swaps with a notional value of 448.0 million, maturing in January 2031.
July 23, 2025	Adoption date of the Clarivate Plc Insider Trading Policy.
August 2025	Amended the revolving credit facility, increasing it from $700.0 million to $775.0 million.
August 2025	Entered into forward-starting swaps with a notional value of $500.0 million, scheduled to commence in October 2026.
August 2025	New provisions of the EU Artificial Intelligence Act (EU AI Act) took effect.
September 2025	Redeemed an additional $100.0 million of outstanding Senior Secured Notes due 2026.
December 9, 2025	Parties filed supplemental briefs in the Pennsylvania state court class action.
December 2025	Entered into a cross-currency swap with a notional value of 448.0 million, maturing in January 2031.
December 31, 2025	End of the fiscal year covered by this annual report.
January 31, 2026	Number of ordinary shares outstanding was 640,698,582.
January 2026	Redeemed the remaining $100.0 million of outstanding Senior Secured Notes due 2026.
February 18, 2026	Court order in Pennsylvania state court class action dismissing the second amended complaint without prejudice, allowing a third amended complaint.
February 24, 2026	Date of certification of the Annual Report on Form 10-K by CEO and CFO.
December 15, 2026	Effective date for ASU 2024-03, Disaggregation of Income Statement Expenses, for annual periods.
October 2026	Maturity date of May 2023 interest rate swaps and commencement date of August 2025 forward-starting swaps.
November 2026	Maturity date of July 2023 cross-currency swap.
December 31, 2026	End date for the current share repurchase program authorization.
December 15, 2027	Effective date for ASU 2024-03, Disaggregation of Income Statement Expenses, for interim reporting periods.
December 15, 2027	Effective date for ASU 2025-06, Targeted Improvements to the Accounting for Internal-Use Software, for fiscal years.
January 2029	Maturity date of the revolving credit facility.
January 2030	Maturity date of August 2025 forward-starting swaps.
May 6, 2030	End date for the updated shareholder share repurchase authority.
January 2031	Maturity date of the term loan facility (Tranche 1 and Tranche 2) and June/December 2025 cross-currency swaps.

Recommendation

hold

Clarivate is in a transitional phase, actively executing a Value Creation Plan that involves strategic divestitures and product streamlining, which has impacted current revenues and Adjusted EBITDA. However, the significant reduction in net loss, improved free cash flow, and higher annual renewal rates indicate positive operational momentum and effective management of the strategic shift. The company's strong focus on AI innovation and debt reduction are favorable long-term indicators. While ongoing legal proceedings introduce some uncertainty, the overall picture suggests a company repositioning for future growth. A 'Hold' recommendation allows investors to observe the continued execution and impact of the Value Creation Plan on sustained profitability and market position.

Keywords

Clarivate, CLVT, 10-K, Annual Report, Financial Results, SEC Filing, Financial Performance, Adjusted EBITDA, Free Cash Flow, Revenue, Net Loss, Subscription Revenue, Annual Renewal Rate, Value Creation Plan, AI Innovation, Artificial Intelligence, Intellectual Property, Academia & Government, Life Sciences & Healthcare, Debt Reduction, Share Repurchase, Goodwill Impairment, Cybersecurity, Data Privacy, Risk Factors, Corporate Governance, Legal Proceedings

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.